BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s share price gapped up prior to trading on Friday . The stock had previously closed at $4.96, but opened at $5.03. BioCryst Pharmaceuticals shares last traded at $5.33, with a volume of 1,666,041 shares trading hands.

A number of research firms have issued reports on BCRX. Jefferies Group upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Wednesday, June 1st. JPMorgan Chase & Co. restated a “hold” rating on shares of BioCryst Pharmaceuticals in a research report on Friday, August 5th. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 9th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, May 9th. Finally, JMP Securities lowered shares of BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $7.89.

The firm’s market cap is $371.41 million. The company has a 50 day moving average of $3.41 and a 200-day moving average of $3.23.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.04. The business had revenue of $4.80 million for the quarter, compared to the consensus estimate of $3.92 million. BioCryst Pharmaceuticals’s revenue for the quarter was down 81.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.06 EPS. On average, equities research analysts expect that BioCryst Pharmaceuticals Inc. will post ($1.03) EPS for the current fiscal year.

In other BioCryst Pharmaceuticals news, insider Thomas R. Staab II sold 14,577 shares of the stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $4.43, for a total transaction of $64,576.11. Following the completion of the transaction, the insider now owns 130,051 shares in the company, valued at $576,125.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Other large investors have recently made changes to their positions in the company. Jennison Associates LLC increased its stake in shares of BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock valued at $13,917,000 after buying an additional 24,014 shares in the last quarter. Globeflex Capital L P purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter valued at $1,241,000. Finally, Morgan Stanley increased its stake in shares of BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock valued at $1,071,000 after buying an additional 12,646 shares in the last quarter.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.